Sebetralstat is a medicine used to treat swelling attacks in people with hereditary angioedema (HAE). It works by blocking a protein that sets off the swelling. It's taken as a pill when an attack starts.
Every report comes from a Lived member, sent anonymously.
Have you tried Ekterly (Sebetralstat) for Hereditary Angioedema?
Sebetralstat, sold as Ekterly, is a prescription tablet for treating attacks of hereditary angioedema (HAE) once they start. HAE is a rare inherited condition that causes repeated episodes of deep swelling, most often in the hands, feet, face, abdomen or throat. Ekterly is approved in the US for adults and children aged 12 and older. Until Ekterly was approved in 2025, the standard treatments for an attack were given by injection or into a vein, such as icatibant (Firazyr) or C1 inhibitor concentrate. Ekterly offers a way to treat an attack by swallowing tablets instead. It treats attacks rather than preventing them, so people who have frequent attacks may also use a separate preventive medicine.
In the most common forms of HAE, the body has too little working C1 inhibitor, a protein that normally keeps an enzyme called plasma kallikrein in check. Without that brake, kallikrein releases a substance called bradykinin, which makes small blood vessels leaky. Fluid seeps into the surrounding tissue, and that is the swelling of an attack. Sebetralstat blocks plasma kallikrein, so less bradykinin is made and the swelling can begin to settle. In studies, it blocked most kallikrein activity within about 30 minutes of a dose. Because bradykinin is already being made once an attack is underway, the medicine works best when taken early.
Ekterly comes as 300 mg tablets. The usual dose is two tablets (600 mg), swallowed as soon as a person recognizes an attack starting. If symptoms are not improving, get worse or come back, a second dose of two tablets can be taken at least 3 hours after the first. No more than four tablets should be taken in 24 hours. It can be taken with or without food. The dose is one tablet instead of two for people with moderate liver disease and for people taking certain other medicines (see Interactions & Warnings). The tablets come in child-resistant blister cards, and the prescriber can explain which dose applies and how many tablets to keep on hand.
Ekterly was well tolerated in its main clinical trial. Headache was the only side effect that appeared more often than with a placebo, and it was uncommon (about 3 in 100 people). Because the trial was fairly small and each person treated only a few attacks, less common side effects may still emerge as more people use it, so any new or troubling symptom is worth reporting to the prescriber.
An attack that involves the throat, with symptoms such as a tight or lumpy feeling in the throat, trouble swallowing, hoarseness or trouble breathing, is a medical emergency because swelling can block the airway. Take the on-demand medicine right away and call 911 or get to an emergency department. Severe throat attacks were not included in the main Ekterly trial. Sebetralstat is broken down in the liver by an enzyme called CYP3A4, so medicines that speed up or slow down that enzyme change how much reaches the bloodstream. Ekterly should not be used with itraconazole (an antifungal medicine), phenytoin (a seizure medicine) or efavirenz (an HIV medicine), and other medicines in the same groups can either raise its level or make it less effective. Some medicines call for the one-tablet dose instead. Share a full list of prescriptions, over-the-counter medicines and supplements with the prescriber and pharmacist, and check before starting anything new. People with severe liver disease should not use Ekterly. There is no information yet on its use during pregnancy or breastfeeding, so anyone pregnant, planning pregnancy or breastfeeding should talk through attack treatment options with their specialist.
In the main trial, about three in four people felt the beginning of relief within 12 hours of taking Ekterly, compared with about half after a placebo, and the typical time to first relief was about 2 hours. About half of attacks had fully resolved within 24 hours, compared with about a quarter with placebo. Nearly 4 in 10 people took a second dose. Guidelines stress treating every attack as early as possible, because early treatment is linked to faster recovery. HAE specialists recommend carrying enough on-demand medicine to treat at least two attacks at all times, since one attack can follow another. If an attack is not getting better after the second dose, contact the HAE care team promptly; they may advise a different on-demand treatment. Keeping a record of attacks and how well each dose worked helps the specialist decide whether the plan, including any preventive treatment, needs to change.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Ekterly (Sebetralstat), what you've noticed, or ask the community a question.